Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report

Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report

<p>Abstract</p> <p>Introduction</p> <p>In the past, no effective systemic therapy has existed for patients with advanced hepatocellular carcinoma. Sorafenib, an oral multikinase inhibitor, has recently been shown to improve overall survival in patients with advanced hep...

Full description

Bibliographic Details
Main Authors: Okuwaki Yusuke, Nakazawa Takahide, Hidaka Hisashi, Shibuya Akitaka, Koizumi Wasaburo
Format: Article
Language:English
Published: BMC 2012-01-01
Series:Journal of Medical Case Reports
Subjects:
Hepatocellular carcinoma
Sorafenib
Late-onset response
Progressive disease
Molecular targeted drug
Online Access:http://www.jmedicalcasereports.com/content/6/1/38

Internet

http://www.jmedicalcasereports.com/content/6/1/38

Similar Items